Cas9 activates the p53 pathway and selects for p53-inactivating mutationsOana M. Enache, Uri Ben‐David, Aaron R. Thorner et al.|Nature Genetics|2020Cited by 285
Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapyVerónica Rendo, Tobias Sjöblom|Nature Communications|2020Cited by 24
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastomaVerónica Rendo, Rameen Beroukhim, Eudocia Q. Lee et al.|Science Translational Medicine|2025Cited by 13
Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancerVerónica Rendo, Tobias Sjöblom|Scientific Reports|2020Cited by 7
A compendium of Amplification-Related Gain Of Sensitivity (ARGOS) genes in human cancerVerónica Rendo, Floris Foijer|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 2